United Therapeutics Corp（UTHR）股票分析UTHRUnited Therapeutics Corp

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

United Therapeutics Corp (UTHR) appears to be a good buy at the current price of $587.50, especially given its strong recent performance with a 5-day change of +10.20% and a 1-year change of +39.54%. The RSI is at 81.515, indicating strong momentum, while the forward P/E ratio of 16.42 suggests it is reasonably valued for future earnings growth. The main risk is the analyst target from Goldman Sachs at $321, indicating a potential downside of 45% from the current price, but the overall sentiment and growth prospects outweigh this risk.

13 analysts cover UTHR: 2 rate it Buy, 6 Hold and 5 Sell. The average price target is 534.50.